Workboat Indexes
Press Releases about Exelixis Inc
![](https://mms.businesswire.com/media/20231018651780/en/1679909/5/Exelixis_Logo_RGB_2023.jpg)
![](https://mms.businesswire.com/media/20230912041846/en/1885889/22/Insilico_logo.jpg)
![](https://mms.businesswire.com/media/20230831134521/en/1679909/5/Exelixis_Logo_RGB_2023.jpg)
From Exelixis
Via Business Wire
![](https://mms.businesswire.com/media/20230823099737/en/1874140/22/Exelixis_Logo_RGB_2023.jpg)
![](https://mms.businesswire.com/media/20230823351775/en/1679909/5/Exelixis_Logo_RGB_2023.jpg)
![](https://mms.businesswire.com/media/20230820936777/en/1870961/22/Exelixis_Logo_RGB_2023.jpg)
![](https://www.marketbeat.com/logos/articles/med_20230816111238_3-strong-biotech-performers-to-watch-as-sector-nea.jpg)
![](https://mms.businesswire.com/media/20230801307436/en/1679909/5/Exelixis_Logo_RGB_2023.jpg)
![](https://www.marketbeat.com/logos/articles/med_20230727124843_7-best-cancer-stocks-to-invest-in-now.jpg)
![](https://mms.businesswire.com/media/20230721235791/en/1847444/22/Exelixis_Logo_RGB_2023.jpg)
![](https://mms.businesswire.com/media/20230718950128/en/1679909/5/Exelixis_Logo_RGB_2023.jpg)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://mms.businesswire.com/media/20230530005657/en/1679909/5/Exelixis_Logo_RGB_2023.jpg)
![](https://www.marketbeat.com/logos/articles/med_20230517121722_analysts-say-these-2-mid-cap-biotechs-have-2x-pote.jpg)
![](https://mms.businesswire.com/media/20230509005349/en/1679909/5/Exelixis_Logo_RGB_2023.jpg)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://mms.businesswire.com/media/20230507005032/en/1679909/5/Exelixis_Logo_RGB_2023.jpg)
![](https://mms.businesswire.com/media/20230503005927/en/1679909/5/Exelixis_Logo_RGB_2023.jpg)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://mms.businesswire.com/media/20230501005641/en/1679909/5/Exelixis_Logo_RGB_2023.jpg)
![](https://mms.businesswire.com/media/20230425006047/en/1679909/5/Exelixis_Logo_RGB_2023.jpg)
![](https://mms.businesswire.com/media/20230413005756/en/1679909/5/Exelixis_Logo_RGB_2023.jpg)
![](https://mms.businesswire.com/media/20230405005800/en/1679909/5/Exelixis_Logo_RGB_2023.jpg)
Exelixis Reiterates Commitment to Shareholder Value Creation
April 05, 2023
From Exelixis, Inc.
Via Business Wire
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://mms.businesswire.com/media/20230320005238/en/1679909/5/Exelixis_Logo_RGB_2023.jpg)
Exelixis Announces $550 Million Share Repurchase Program
March 20, 2023
From Exelixis, Inc.
Via Business Wire
![](https://mms.businesswire.com/media/20230313005670/en/1679909/5/Exelixis_Logo_RGB_2023.jpg)
![](https://mms.businesswire.com/media/20230302005857/en/1728975/22/Exelixis_Logo_RGB_2023.jpg)
![](https://mms.businesswire.com/media/20230228006371/en/1679909/5/Exelixis_Logo_RGB_2023.jpg)
From Exelixis, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.